Trials / Approved For Marketing
Approved For MarketingNCT04056481
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).
Detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Givosiran | givosiran (ALN-AS1) administered as a subcutaneous (SC) injection |
Timeline
- First posted
- 2019-08-14
- Last updated
- 2024-05-20
Source: ClinicalTrials.gov record NCT04056481. Inclusion in this directory is not an endorsement.